Latest News

Date Title Topic
08 Sep 2017 ESMO 2017: Rucaparib Shows Clinical Benefit as Maintenance Therapy in Patients with Recurrent Ovarian Cancer Gynaecologic malignancies - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Adding Abiraterone Acetate or Docetaxel Plus Prednisone to Standard of Care in Patients with High-Risk Prostate Cancer Genitourinary cancers - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Combined Taselisib and Letrozole Improves Response in Postmenopausal Women with ER-positive, HER-negative Early Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Pembrolizumab Demonstrates Antitumour Activity in Advanced Gastric Cancer as Monotherapy and Combined with Chemotherapy Gastrointestinal cancers - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017: Invasive DFS Rates Following Trastuzumab are Improved with Neratinib Over Placebo in Early Stage HER2-positive Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
08 Sep 2017 ESMO 2017 Daily Reporter
08 Sep 2017 ESMO 2017 Press Release: Rucaparib Boosts Progression-free Survival in BRCA Mutant Recurrent Ovarian Cancer Gynaecologic malignancies
08 Sep 2017 ESMO 2017 Press Release: Pembrolizumab: Promising Response Rate in Pretreated Metastatic Gastric Cancer Gastrointestinal cancers
08 Sep 2017 ESMO 2017 Press Release: Patients with High Risk Prostate Cancer May Benefit “Equally” From Two New Treatments Genitourinary cancers
08 Sep 2017 ESMO 2017 Press Release: DNA Sequencing Could Open Up New Drug Indications for Patients with Rare Cancers Translational research
08 Sep 2017 ESMO 2017 Press Release: New Data Confirms Superiority of Docetaxel Based Triplet Therapy in Gastric Cancer Gastrointestinal cancers
08 Sep 2017 ESMO 2017 Press Release: LORELEI: Taselisib Boosts Breast Tumor Shrinkage Breast cancer